“Although JAK inhibitors have been approved for a range of autoimmune and inflammatory conditions in the general population, this clinical trial, which started activities back in 2020, provides the ...

An unprecedented study reveals strategy to decrease the burden of alopecia areata, atopic dermatitis, psoriasis and other autoimmune conditions. A new study published in eLIFE by researchers from the ...

Rese-cel data presented at multiple medical meetings demonstrated potentially transformative, drug-free clinical responses with a favorable safety profile for autoimmune patients supporting outpatient ...

Cabaletta Bio, Inc. announced promising results from its ongoing RESET clinical trials for its investigational therapy rese-cel, focusing on autoimmune diseases. In the trials, notable outcomes ...

Cabaletta Bio, Inc. announced promising clinical data regarding its investigational therapy, resecabtagene autoleucel (rese-cel), for autoimmune diseases during recent scientific meetings. Among the ...